ViroCure

ViroCure is a pioneering company at the forefront of cancer therapeutics research and vaccine development with oncolytic virotherapy. The company is dedicated to discovering and developing unique viruses to safely and effectively treat various types of cancer illnesses with no current cure regimen. ViroCure's goal is to find and catalog many different oncolytic viral or vaccine species for cancer and other therapeutics in the near future. Their naturally occurring, modified, engineered viruses selectively infect and kill cancer cells and activate anti-cancer immune responses, with negligible side effects on normal cells. Founded in 2016 and headquartered in South Korea, ViroCure holds 6 patents spanning 4 countries, including the United States, with multiple upcoming patents already in progress. The company is poised to become a market leader in the new fourth generation of cancer therapeutics.